Biotest GmbH KGaA (LTS:0N6Z) Net Margin %: 0.00% (As of . 20)


What is Biotest GmbH KGaA Net Margin %?

Biotest GmbH KGaA LTS:0N6Z Net Margin % is 0.00% as of . 20.

Net margin is calculated as Net Income divided by its Revenue. Biotest GmbH KGaA's Net Income for the six months ended in . 20 was £0.00 Mil. Biotest GmbH KGaA's Revenue for the six months ended in . 20 was £0.00 Mil. Therefore, Biotest GmbH KGaA's net margin for the quarter that ended in . 20 was 0.00%.

The historical rank and industry rank for Biotest GmbH KGaA's Net Margin % or its related term are showing as below:


LTS:0N6Z's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.295
* Ranked among companies with meaningful Net Margin % only.

Biotest GmbH KGaA  (LTS:0N6Z) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Biotest GmbH KGaA Net Margin % Related Terms

Biotest GmbH KGaA Net Margin % Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA Net Margin % Chart

Biotest GmbH KGaA Annual Data
Trend
Net Margin %

Biotest GmbH KGaA Semi-Annual Data
Net Margin %

LTS:0N6Z vs : Net Margin % Comparison

For the Biotechnology subindustry, Biotest GmbH KGaA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biotest GmbH KGaA Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biotest GmbH KGaA's Net Margin % distribution charts can be found below:

* The bar in red indicates where Biotest GmbH KGaA's Net Margin % falls into.


Biotest GmbH KGaA Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Biotest GmbH KGaA's Net Margin for the fiscal year that ended in . 20 is calculated as

Net Margin=Net Income (A: . 20 )/Revenue (A: . 20 )
=/
= %

Biotest GmbH KGaA's Net Margin for the quarter that ended in . 20 is calculated as

Net Margin=Net Income (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Net Margin % of 0.00% as of . 20. Net margin is the ratio of total net income to net sales. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's Net Margin % too high?
Biotest GmbH KGaA's current Net Margin % is 0.00%.
How does Biotest GmbH KGaA's Net Margin % compare to ?
Biotest GmbH KGaA's Net Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Net Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.